PDF(Pubmed)
Abstract：
UNASSIGNED: Tislelizumab is the first PD-1 inhibitor in China to demonstrate superior efficacy in second-line or third-line treatment of patients with advanced or metastatic non-small-cell lung cancer (NSCLC). This study aimed to evaluate the cost-effectiveness of tislelizumab compared to docetaxel from a Chinese healthcare system perspective.
UNASSIGNED: A dynamic Markov model was developed to evaluate the cost-effectiveness of tislelizumab in comparison to docetaxel in second or third-line treatment. The efficacy data utilized in the model were derived from the RATIONALE-303 clinical trial, while cost and utility values were obtained from the drug data service platform and published studies. The primary outcomes of the model encompassed quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to validate the robustness of the base case analysis results.
UNASSIGNED: The tislelizumab group demonstrated a cost increase of CNY 117,473 and a gain of 0.58 QALYs compared to the docetaxel group, resulting in an ICER value of CNY 202,927 per QALY gained.
UNASSIGNED: The administration of tislelizumab in patients with advanced or metastatic NSCLC not only extends the progression-free survival (PFS) and overall survival (OS). Moreover, this treatment demonstrates a favorable cost-effectiveness profile across the Chinese population.
UNASSIGNED: A dynamic Markov model was developed to evaluate the cost-effectiveness of tislelizumab in comparison to docetaxel in second or third-line treatment. The efficacy data utilized in the model were derived from the RATIONALE-303 clinical trial, while cost and utility values were obtained from the drug data service platform and published studies. The primary outcomes of the model encompassed quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to validate the robustness of the base case analysis results.
UNASSIGNED: The tislelizumab group demonstrated a cost increase of CNY 117,473 and a gain of 0.58 QALYs compared to the docetaxel group, resulting in an ICER value of CNY 202,927 per QALY gained.
UNASSIGNED: The administration of tislelizumab in patients with advanced or metastatic NSCLC not only extends the progression-free survival (PFS) and overall survival (OS). Moreover, this treatment demonstrates a favorable cost-effectiveness profile across the Chinese population.
摘要：
■Tislelizumab是中国第一个在二线或三线治疗晚期或转移性非小细胞肺癌（NSCLC）患者中表现出优异疗效的PD-1抑制剂。本研究旨在从中国医疗保健系统的角度评估tislelizumab与多西他赛的成本效益。
■开发了一种动态马尔可夫模型来评估tislelizumab与多西他赛在二线或三线治疗中的成本效益。模型中使用的疗效数据来自RATIONAL-303临床试验，而成本和效用值是从药物数据服务平台和已发表的研究中获得的。该模型的主要结果包括质量调整生命年(QALYs)，成本,和增量成本效益比(ICER)。进行了单向敏感性分析和概率敏感性分析，以验证基本情况分析结果的鲁棒性。
■与多西他赛组相比，tislelizumab组的成本增加了117,473元，增加了0.58个QALY，导致每QALY获得202,927元人民币的ICER值。
在晚期或转移性NSCLC患者中使用tislelizumab不仅延长了无进展生存期（PFS）和总生存期（OS）。此外，这种治疗在中国人群中表现出良好的成本效益.
■开发了一种动态马尔可夫模型来评估tislelizumab与多西他赛在二线或三线治疗中的成本效益。模型中使用的疗效数据来自RATIONAL-303临床试验，而成本和效用值是从药物数据服务平台和已发表的研究中获得的。该模型的主要结果包括质量调整生命年(QALYs)，成本,和增量成本效益比(ICER)。进行了单向敏感性分析和概率敏感性分析，以验证基本情况分析结果的鲁棒性。
■与多西他赛组相比，tislelizumab组的成本增加了117,473元，增加了0.58个QALY，导致每QALY获得202,927元人民币的ICER值。
在晚期或转移性NSCLC患者中使用tislelizumab不仅延长了无进展生存期（PFS）和总生存期（OS）。此外，这种治疗在中国人群中表现出良好的成本效益.
